In a phase-II clinical trial, Keefe and colleagues85 assessed the efficacy of encenicline, a selective α7nAChR agonist, in the treatment of cognitive impairment in patients with schizophrenia. This evidence concerns the gene CHRNA7 and Cognitive impairment.